SELECTBIO Conferences Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024

Æ÷½ºÅÍ ¹ßÇ¥


Æ÷½ºÅÍ Á¦Ãâ ¸¶°¨ÀÏ : 2024³â 9¿ù 15ÀÏ

Á¦ÃâµÈ Æ÷½ºÅÍ °³¿ä´Â ¸ðµÎ °úÇÐ ÀÚ¹®À§¿øÈ¸¿¡ ÀÇÇØ ½É»çµÇ¸ç, ½ÅûÀÚ¿¡°Ô´Â ±× °á°ú°¡ Å뺸µË´Ï´Ù.

½ÂÀÎµÈ ½ÅûÀÚ¿¡°Ô´Â ÇÊ¿äÇÑ Á¤º¸°¡ ¸ðµÎ Á¦°øµË´Ï´Ù.

°³¿ä ³»¿ë :

  • ÀüºÎ ¿µ¾î·Î ±âÀçÇÒ °Í
  • »ïÀÎĪÀ¸·Î ±â¼úÇÒ °Í
  • ŸÀÌÆ²¡¤ÀúÀÚ¸í¡¤ÀúÀÚÀÇ ¼Ò¼Óó¸¦ ±âÀçÇÒ °Í
  • 100-200 ¿öµå À̳»
  • ȸÀÇ·Ï ¹× À¥»çÀÌÆ®¿¡ ´ëÇÑ Á÷Á¢ °ÔÀç¿¡ ÀûÇÕÇÑ Çü½ÄÀ¸·Î ÇÒ °Í
  • ÄÁÆÛ·±½º ÁÖÁ¦¿¡ °ü·ÃÇÒ °Í

¾ÆÁ¨´Ù ÅäÇÈ

  • Circulating Biomarkers: cfDNA, RNA, EVs, Others
    ¼øÈ¯ ¹ÙÀÌ¿À¸¶Ä¿ : cfDNA, RNA, EV µî
  • Novel Biomarker Classes for Diagnostics Development
    Áø´ÜÇÐ ¹ßÀüÀ» À§ÇÑ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ Ŭ·¡½º
  • Regulatory Landscape for Diagnostics in the US, circa 2024
    ¹Ì±¹¿¡¼­ Áø´ÜÇÐÀÇ ±ÔÁ¦ »óȲ(2024³â°æ)
  • Technologies for Deploying Biomarkers into Novel Diagnostics Classes
    ½Å±Ô Áø´Ü Ŭ·¡½º¿¡ ´ëÇÑ ¹ÙÀÌ¿À¸¶Ä¿ µµÀÔÀ» À§ÇÑ ±â¼ú

ÀúÀÛ±Ç

°³¿ä¸¦ Á¦ÃâÇÑ ¹ßÇ¥ÀÚ/°³ÀÎÀº °³¿ä¿¡ ±âÀçµÈ ³»¿ë¿¡ ´ëÇØ ¸ðµç Ã¥ÀÓÀ» Áö¸ç, °øÀúÀÚ Àü¿øµµ ÀÌ »ç½ÇÀ» ¾Ë°í ÀÖ´Â °ÍÀ¸·Î ÇÕ´Ï´Ù. Á¦ÃâÀÚÀÇ °æ·Â¼­ ¹× ¿ä¾à¡¤°³¿ä´Â ÀÌ À¥»çÀÌÆ® ¹× ÄÁÆÛ·±½º ÀÚ·á¿¡ »ç¿ëµÉ ¼ö ÀÖÀ¸¹Ç·Î ¾çÇØ ¹Ù¶ø´Ï´Ù.


ÇØ´ç ÄÁÆÛ·±½º´Â Á¾·áµÇ¾ú½À´Ï´Ù.
Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English_